| UHC UMR Medical and Drug | Adakveo® (Crizanlizumab-Tmca) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC UMR Medical and Drug | Edaravone – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC UMR Medical and Drug | Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC UMR Medical and Drug | Qalsody® (Tofersen) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC UMR Medical and Drug | RNA-Targeted Therapies (Amvuttra® and Onpattro®) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC UMR Medical and Drug | Trogarzo® (Ibalizumab-Uiyk) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC UMR Medical and Drug | Veopoz® (Pozelimab-Bbfg) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC Surest Medical and Drug | Adakveo® (Crizanlizumab-Tmca) – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC Surest Medical and Drug | Edaravone – Commercial Medical Benefit Drug Policy | 2025-06-01 |
| UHC Surest Medical and Drug | Intravenous Enzyme Replacement Therapy (ERT) for Gaucher Disease – Commercial Medical Benefit Drug Policy | 2025-06-01 |